Clinical trials: Recurrent Endometrial Clear Cell Adenocarcinoma
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer.
- Conditions
- Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT00575952
- Testing
- Cisplatin, Doxorubicin Hydrochloride, Filgrastim
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01100359
- Testing
- carboplatin, liposome-encapsulated doxorubicin citrate, laboratory biomarker analysis
- Where
- Austria
- Volunteers
- 39 people
- Sponsor
- Medical University Innsbruck
Endometrial Cancer
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003127
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- 94 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT00888173
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 35 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00820898
- Testing
- Gemcitabine Hydrochloride
- Where
- 20 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05112601
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 138 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma
- Trial name
- NCT00072176
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT02065687
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride
- Where
- 431 sites in United States
- Volunteers
- 469 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT01210222
- Testing
- Trebananib
- Where
- 33 sites in United States
- Volunteers
- 35 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
This pilot phase I trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV, or endometrial cancer that has come back after a period of improvement.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01440998
- Testing
- Carboplatin, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01150682
- Testing
- RNA analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay
- Volunteers
- 865 people, healthy volunteers welcome
- Sponsor
- Gynecologic Oncology Group
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Lynch Syndrome, Recurrent Endometrial Carcinoma
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent).
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma
- Trial name
- NCT04906382
- Testing
- Biopsy, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Floor Backes, MD
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT05049538
- Testing
- Biospecimen Collection, Liquid Biopsy, Pap Smear
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Trial name
- NCT05950464
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)